BriaCell's Annual General Meeting Update
PHILADELPHIA and VANCOUVER — BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT), a pioneering clinical-stage biotechnology firm dedicated to groundbreaking immunotherapies designed to revolutionize cancer treatment, has announced an important change regarding its upcoming Annual General Meeting of Shareholders. The meeting originally scheduled for a Thursday in January has now been postponed to February 5, at 9:00 a.m. (ET). This decision was made to accommodate delays linked to postal service interruptions and to ensure ample time for securing proxy votes from shareholders.
Understanding the Meeting's Purpose
The meeting, set to occur at Suite 3400, One First Canadian Place in Toronto, will cover vital discussions including the receipt of audited financial statements and auditor's report, election of directors for the approaching year, and the appointment of auditors along with their remuneration. BriaCell’s Board of Directors strongly endorses the proposals outlined in the proxy statement for the gathering.
What Shareholders Need to Know
Shareholders who have already submitted their votes need not take additional steps unless they wish to modify or cancel their previous instructions. Their submissions will still be counted during the postponed meeting. Those who have not voted are encouraged to cast their votes promptly to ensure they can be included in the tally before the meeting date.
How to Vote: A Guide for Shareholders
Shareholders categorized as registered, meaning they hold shares directly within the company rather than through intermediaries like brokerage accounts, can obtain their voting control numbers by contacting Computershare Shareholder Services at 1-800-564-6253 (Canada/US) or 1-514-982-7555 for international inquiries. For beneficial shareholders, there are two classifications: Objecting Beneficial Owners (OBOs) and Non-Objecting Beneficial Owners (NOBOs). The company will send materials directly to NOBOs, who can then submit their votes via the Voting Instruction Form available on BriaCell’s website or by emailing Computershare.
Voting Options Made Easy
Shareholders are urged to participate in the voting process via telephone or the internet, ensuring they have a say in the company’s direction:
- Online voting: www.investorvote.com
- Toll-Free Telephone: 1-866-732-VOTE (8683)
Assistance for Shareholders
For those needing support with their proxy voting, BriaCell’s proxy solicitation agent, Sodali, is available to assist:
- North American Toll-Free Number: 1-888-444-0591
- Outside North America (collect calls accepted): 1-289-695-3075
- Email: assistance@investor.sodali.com
About BriaCell Therapeutics
BriaCell is at the forefront of developing innovative immunotherapies aimed at transforming the landscape of cancer care. Their commitment to advancing treatment options is complemented by a robust pipeline of promising therapies. To learn more about the company and its mission, visit their official site at briacell.com.
Frequently Asked Questions
1. Why was the Annual General Meeting rescheduled?
The meeting was postponed due to postal service disruptions and to allow more time for shareholders to submit their proxy votes.
2. How can shareholders vote in the postponed meeting?
Shareholders can vote online, via telephone, or by mailing a Voting Instruction Form to Computershare before the deadline.
3. What will be discussed during the meeting?
Key discussions include the election of directors, the appointment of auditors, and the approval of financial statements.
4. Who can I contact for assistance regarding voting?
Shareholders can reach out to BriaCell’s proxy solicitation agent, Sodali, or contact Computershare for help with their voting inquiries.
5. Where can I find BriaCell’s Proxy Statement?
The Proxy Statement can be accessed through the company’s profile on EDGAR and SEDAR+, as well as on BriaCell's official website.
